Schizophrenia Clinical Trials

Find Schizophrenia Clinical Trials Near You

Deep Brain Stimulation for Treatment-Refractory Schizophrenia: Individualized Target Selection and Efficacy

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia. Using stereo-electroencephalography (SEEG) to record brain activity, we will identify specific abnormal electrophysiological targets and signal features associated with clinical symptoms, followed by a 12-month open-label stimulation period. The study is conducted in three stages: Stage 1 consists of SEEG brain mapping, screening of intervention targets, and optimization of stimulation parameters; Stage 2 consists of DBS implantation surgery and further optimization of stimulation parameters; Stage 3 is a randomized crossover treatment phase, followed by an open-label treatment period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:

• Meets the International Classification of Diseases, 10th Revision (ICD-10) diagnostic criteria for schizophrenia.

• Male or female, aged 18 to 55 years, with stable vital signs.

• Currently presents with prominent psychotic symptoms, assessed as moderate or severe by the Positive and Negative Syndrome Scale (PANSS) or other equivalent scales.

• Exhibits impaired social functioning, assessed as moderate or severe impairment by the Social and Occupational Functioning Assessment Scale (SOFAS) or other equivalent scales.

• Has a history of sequential treatment with at least two antipsychotic medications of different chemical structures known for strong efficacy against positive symptoms. Treatment must have been at an adequate dose and for an adequate duration (continuous treatment at a therapeutic dose for more than 6 weeks per medication), with good treatment adherence.

• Has been on a stable antipsychotic medication regimen for at least one month prior to enrollment.

• Capable and willing to provide written informed consent.

• Demonstrates good compliance and is able to cooperate with all follow-up procedures.

Locations
Other Locations
China
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Shuo Ma, PhD
ms13144@rjh.com.cn
86+15000838003
Time Frame
Start Date: 2025-08-17
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 46
Treatments
Active_comparator: Stim ON-OFF
Participants randomized to the Stim ON-OFF arm will first undergo bilateral stereoelectroencephalography (SEEG) electrode implantation targeting brain regions associated with schizophrenia symptoms, followed by stimulation response assessments.~Secondly, deep brain stimulation will be performed based on the electrophysiological recordings and stimulation assessment results.~Thirdly, participants will receive active stimulation during the randomization phase for up to 12 weeks. The participants will then have their device turned off and receive sham stimulation during the crossover phase for up to 12 weeks.
Placebo_comparator: Stim OFF-ON
Participants randomized to the Stim OFF-ON arm will first undergo bilateral stereoelectroencephalography (SEEG) electrode implantation targeting brain regions associated with schizophrenia symptoms, followed by stimulation response assessments.~Secondly, deep brain stimulation will be performed based on the electrophysiological recordings and stimulation assessment results.~Thirdly, participants will have their device turned off and receive sham stimulation during the randomization phase for up to 12 weeks. The participants will then receive active stimulation during the crossover phase for up to 12 weeks.
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital

This content was sourced from clinicaltrials.gov